X

Trial Profile

A Phase 2/3 Pivotal Trial to Evaluate AER-901 for the Treatment of Pulmonary Arterial Hypertension (PAH)

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 27 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary)
Indications Pulmonary arterial hypertension
Focus Registrational; Therapeutic Use
Sponsors Aerami Therapeutics

Most Recent Events

25 Aug 2021 According to an Aerami Therapeutics media release, the company plans to initiate this study in the first half of 2022
16 Feb 2021 New trial record
09 Feb 2021 According to an Aerami Therapeutics media release, Aerami targets initiation of this pulmonary arterial hypertension pivotal trial early in 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com